Current Medical Science最新文献

{"title":"Targeting GLUTs in Cancer: Mechanisms, Combination Strategies, and Translational Challenges.","authors":"Mei-Na Shi, Dong-Fan Yang, Tong Chu, Da-Yuan Zheng, Wen-Zhe Ma","doi":"10.1007/s11596-026-00245-1","DOIUrl":"https://doi.org/10.1007/s11596-026-00245-1","url":null,"abstract":"<p><p>Cancer cells exhibit metabolic reprogramming, most notably the Warburg effect, which underscores their heightened dependency on glucose uptake facilitated by glucose transporters (GLUTs). While targeting GLUTs holds promise for disrupting tumor metabolism, monotherapeutic inhibition often leads to compensatory resistance mechanisms, metabolic plasticity, and dose-limiting toxicity. This review comprehensively examines the rationale and mechanisms underlying combined strategies that integrate GLUT inhibitors with conventional chemotherapy, targeted therapy, immunotherapy, and radiotherapy. Such combinations exploit synthetic lethality, reverse immunosuppression, enhance DNA damage, and overcome adaptive resistance. We also discuss emerging approaches such as isoform-specific inhibitors, nanocarrier-based delivery, and artificial intelligence-guided combination design to improve selectivity and efficacy. Finally, we highlight key translational challenges and discuss how cross-disease insights into GLUT biology may inform the safety, selectivity, and therapeutic design of cancer-directed GLUT-targeted combination strategies.</p>","PeriodicalId":10820,"journal":{"name":"Current Medical Science","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148873183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NCOA1 Attenuates High Glucose-Induced Mesangial Matrix Expansion Through ITGA5 Inhibition.","authors":"Shu-Xin Song, Li-Li Gai, Chun-Tao Lei","doi":"10.1007/s11596-026-00244-2","DOIUrl":"https://doi.org/10.1007/s11596-026-00244-2","url":null,"abstract":"<p><strong>Objective: </strong>To investigate whether nuclear receptor coactivator 1 (NCOA1) participates in the pathogenesis of diabetic kidney disease (DKD) by modulating extracellular matrix (ECM) production in mesangial cells (MCs), and to explore the underlying molecular mechanism.</p><p><strong>Methods: </strong>The rat glomerular MCs and streptozotocin-induced DKD mouse models were employed. NCOA1 expression was evaluated under both normal and high-glucose conditions. The functional role of NCOA1 was assessed via plasmid-mediated overexpression in high-glucose treated MCs. Integrin alpha 5 (ITGA5) expression was examined in vivo and in vitro, and its regulatory relationship with NCOA1 was investigated. Furthermore, siRNA-mediated knockdown of ITGA5 was performed to determine its necessity in high-glucose driven ECM overproduction.</p><p><strong>Results: </strong>NCOA1 was abundantly expressed in resting MCs but markedly downregulated upon high-glucose stimulation. Plasmid-driven overexpression of NCOA1 significantly attenuated high-glucose induced ECM protein synthesis. Notably, ITGA5 expression was substantially elevated in the glomerular mesangium of DKD mice and in high-glucose exposed MCs, and this upregulation was negatively governed by NCOA1. Functionally, ITGA5 silencing effectively abrogated the excessive matrix production provoked by high glucose, phenocopying the protective effect of NCOA1 overexpression.</p><p><strong>Conclusion: </strong>NCOA1 protects against high-glucose induced mesangial expansion in DKD, at least partially, through negative regulation of ITGA5. These findings identify the NCOA1/ITGA5 axis as a potential therapeutic target for counteracting glomerular fibrosis in DKD.</p>","PeriodicalId":10820,"journal":{"name":"Current Medical Science","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148863899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nose-to-Brain Nanocarriers for Migraine Management: A Comprehensive Review of Drug Delivery Strategies and Translational Challenges.","authors":"Hala Bashtawi, Mohammad A Obeid","doi":"10.1007/s11596-026-00229-1","DOIUrl":"https://doi.org/10.1007/s11596-026-00229-1","url":null,"abstract":"<p><p>Migraine is among the most prevalent neurological disorders and can affect people's daily activities because of high- and long-lasting pain intensity attacks. The available dosage forms, such as oral and parenteral formulations, can enhance patients' symptoms but still have poor side effects, bioavailability, or dosing difficulty. As a result, there is an urgent need to find other novel drug delivery systems (DDSs) to treat migraine. The intranasal (IN) route was investigated as an alternative pathway to deliver therapeutic molecules directly to the brain, bypassing the blood-brain barrier (BBB) and hepatic first-pass metabolism. Nanocarriers facilitate drug transportation regardless of their lipophilicity, resulting in more efficient drug absorption and bioavailability. They also effectively contribute to brain targeting, which maximizes the therapeutic effect of drugs. This review discusses the efficacy of nanocarriers loaded with antimigraine agents and delivered by the IN route in the management of migraine. In preclinical studies, nanocarriers such as liposomes, ethosomes, nanostructured lipid carriers, and many others have been used to enhance brain targeting. Studies have focused on obtaining high results for brain pharmacokinetics, such as drug targeting efficiency (DTE) and direct transport percentage (DTP). This leads to better drug accumulation and a rapid onset of action. Despite the proven success of preclinical studies on the delivery of migraine drugs loaded with nanocarriers through the IN route, there is still a shortage in translating this success into the clinical stage.</p>","PeriodicalId":10820,"journal":{"name":"Current Medical Science","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148766049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Analysis of Organ Transplantation-Specific Agent Based on Large Language Model in Post-Transplant Self-Management During Off-Hours: A Mixed-Methods Study.","authors":"Cheng Zeng, Xin Zhou, Hong-Yun Xu, Xiao-Ping Zhu, Yue Shi, Guang-le Dai, Zhi-Gao Deng, Yan Xu, Li Xu, Hui Xiao, Shao-Jun Ye","doi":"10.1007/s11596-026-00219-3","DOIUrl":"10.1007/s11596-026-00219-3","url":null,"abstract":"<p><strong>Objective: </strong>A significant gap exists in medical support for organ transplant patients during out-of-hours (OOH). General large language models (LLMs), affected by AI hallucinations, are unsuitable for complex post-transplant care. We built the first post-transplant AI agent based on LLMs to address these issues.</p><p><strong>Methods: </strong>We constructed a specialized \"post-transplant AI agent\" (named Doctor Xiao Yi) and conducted a mixed-methods study comparing it to a hospital-wide general AI agent (named Nan Xiao Yi). Data included 20,176 real-world logs (June-December 2025) and a cross-sectional survey of 152 transplant patients. We examined patterns of use over time, the types of questions raised, and the factors influencing patient behavior.</p><p><strong>Results: </strong>Unlike Nan Xiao Yi, Doctor Xiao Yi remained active during OOH, with a peak at 4:00 AM (P < 0.001). The general agent handled admin tasks like appointments, while the specialist agent provided clinical support such as diet, symptoms, and medication. Survey found 60.5% of OOH use by transplant patients due to reluctance to disturb human doctors. Furthermore, 63.8% of transplant patients were satisfied with the specialist agent's responses, and 48% reported they would decide on further hospital treatment based on AI suggestions.</p><p><strong>Conclusions: </strong>The specialist AI agent effectively fills the gap in medical and psychological services during OOH for transplant recipients. Based on the \"dual-source knowledge base + GraphRAG + multi-agent framework\" architecture, our specialist AI agent offers safe, reliable post-transplant care.</p>","PeriodicalId":10820,"journal":{"name":"Current Medical Science","volume":" ","pages":"1004-1013"},"PeriodicalIF":2.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13503416/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148359827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Value of Admission Renal Injury-Related Indicators for Fatal Outcomes in Patients with Severe Fever with Thrombocytopenia Syndrome.","authors":"Xing Chen, Li Yan, Xu Xiang","doi":"10.1007/s11596-026-00228-2","DOIUrl":"10.1007/s11596-026-00228-2","url":null,"abstract":"<p><strong>Objective: </strong>Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease with high mortality rates. While previous studies have focused primarily on the epidemiological and clinical aspects of SFTS, indicators of renal injury at admission have received limited attention.</p><p><strong>Methods: </strong>We retrospectively analyzed 260 patients with SFTS admitted to the study hospital between April 1, 2023, and July 18, 2024, who were classified into the survival group (n = 163) and death group (n = 97) on the basis of 28-day prognosis. Renal-related data were collected upon admission. Univariate and multivariate Cox regression analyses were used to identify independent predictors, and a nomogram was constructed. Receiver operating characteristic (ROC) curves and calibration curves were used to assess the discrimination and calibration of the model. Kaplan-Meier curves were used to assess the cumulative survival rate of patients with these risk factors. External validation was conducted in 40 patients with SFTS who were admitted to an affiliated branch hospital during the same period.</p><p><strong>Results: </strong>The 28-day mortality rate was 37.3% (97/260). Multivariate analysis revealed age (HR = 1.053; 95% CI 1.027-1.079; P < 0.001), viral load (HR = 2.006; 95% CI 1.684-2.390; P < 0.001), and UREA (HR = 1.059; 95% CI 1.027-1.093; P < 0.001) as independent risk factors. The area under the curve (AUC) of the nomogram was 0.900 (95% CI 0.861-0.937), with 82.5% sensitivity and 84.0% specificity at the optimal cutoff (0.292). The calibration curve showed close agreement between the predicted and observed probability lines, indicating good model calibration. External validation yielded an AUC of 0.863 (95% CI 0.723-0.954), confirming favorable performance.</p><p><strong>Conclusion: </strong>Renal injury-related indicators at admission were strongly associated with fatal outcomes in patients with SFTS. Nomograms based on age, viral load, and UREA provide accurate and easily applicable tools for early risk stratification and may support individualized clinical management.</p>","PeriodicalId":10820,"journal":{"name":"Current Medical Science","volume":" ","pages":"1089-1098"},"PeriodicalIF":2.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148469146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Invasiveness, SOX2 Expression, and Resection Outcomes in TF-Defined PitNETs After Extra-Pseudocapsular Resection.","authors":"Xing-Bo Li, Kuo Zeng, Xue-Yan Wan, Hui-Yong Liu, Liang Lu, Juan Chen, Chang-Shu Ke, Jun-Wen Wang, Ting Lei","doi":"10.1007/s11596-026-00231-7","DOIUrl":"10.1007/s11596-026-00231-7","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the associations between transcription factor (TF)-defined molecular lineages and the clinical characteristics of pituitary neuroendocrine tumors (PitNETs).</p><p><strong>Methods: </strong>A retrospective cohort analysis was performed in 274 patients who underwent extra-pseudocapsular transsphenoidal resection. Tumors were classified by TF-defined lineage and invasion grade (0-3) and Knosp score. Group differences were tested, and predictors of gross total resection (GTR) were examined using hierarchical multivariable logistic regression.</p><p><strong>Results: </strong>TF-defined lineage classification improved diagnostic precision. Among tumors with an immunonegative hormone profile, 74.7% received a definitive lineage assignment. The pituitary transcription factor 1-growth hormone/prolactin (PIT1-GH/PRL) subgroup had the highest incidence and grade of invasion; SRY-box transcription factor 2 (SOX2) positivity was most frequent in this subgroup (41.7%), which also exhibited the lowest GTR rate (58.3%). SOX2-positive tumors were associated with significantly higher preoperative adrenocorticotropic hormone (ACTH) (median: 38.80 vs. 31.60 pg/mL, P = 0.032) and GH (median: 1.12 vs. 0.43 ng/mL, P = 0.046) levels. SOX2 positivity was 20.5% in multilineage tumors and 20.0% in the recurrent cohort (n = 20). Compared with Trouillas grade alone, the combination of invasion grade and intraoperative features (capsule status and vascularity) significantly improved the ability to predict GTR (AUC, 0.866 vs. 0.795; ΔAUC = 0.071; DeLong 95% CI, 0.022-0.120; P = 0.005).</p><p><strong>Conclusions: </strong>The 2022 WHO TF-defined lineage system improves diagnostic precision and facilitates the interpretation of PitNET differentiation and molecular pathology. Tumors in the PIT1-GH/PRL subgroup demonstrate more aggressive invasive features. SOX2 positivity was relatively frequent in multilineage tumors, whereas the observation in recurrent cases was limited by the small exploratory cohort and requires validation in larger longitudinal studies.</p>","PeriodicalId":10820,"journal":{"name":"Current Medical Science","volume":" ","pages":"1046-1057"},"PeriodicalIF":2.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood ACE Activity Is Significantly Lowered in Psoriasis Compared to Atopic Dermatitis: A Small Pilot Study in Young Males.","authors":"Vivien Osterhus, Markus Böhm, Simone König","doi":"10.1007/s11596-026-00232-6","DOIUrl":"10.1007/s11596-026-00232-6","url":null,"abstract":"<p><strong>Purpose: </strong>Emerging evidence suggests the involvement of the renin-angiotensin system (RAS) in the pathogenesis and progression of autoimmune dermatological diseases. In a small exploratory study, we investigated angiotensin-converting enzyme (ACE) activity in blood obtained from male probands with psoriasis vulgaris (n = 4) and atopic dermatitis (AD, n = 5).</p><p><strong>Methods: </strong>The degradation capacity of dabsylated synthetic bradykinin (DBK) with and without inhibition was determined using a thin-layer chromatography (TLC)-based neuropeptide reporter assay.</p><p><strong>Results: </strong>We observed a significantly reduced capacity for cleavage of DBK in psoriasis patients compared with that in AD patients and controls. In patient samples, the variation in the measured values was generally greater than that in healthy controls. We could not confirm the increased ACE activity in the circulation in psoriasis patients reported by others, likely because of different study designs and detection methods. We did not include samples of female patients and focused on younger men to avoid hormonal effects and minimize age-related factors.</p><p><strong>Conclusion: </strong>This preliminary study of the hypothesis-generating nature lacks power, but it certainly adds a question to the current view of the role of ACE in psoriasis. Treatments targeting specific components of the RAS could ameliorate inflammatory responses; thus, research in this area is becoming increasingly important.</p>","PeriodicalId":10820,"journal":{"name":"Current Medical Science","volume":" ","pages":"1115-1120"},"PeriodicalIF":2.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13503464/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148520137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"KLF4 in Parkinson's Disease: Decoding the Molecular Puzzle of Neuroinflammation, Oxidative Stress, and Emerging Therapies.","authors":"Anjali Kumari, Khadga Raj Aran","doi":"10.1007/s11596-026-00230-8","DOIUrl":"10.1007/s11596-026-00230-8","url":null,"abstract":"<p><p>Parkinson's disease (PD) is the most prevalent neurodegenerative movement condition. Tremors, stiffness, bradykinesia/akinesia, and postural instability are its primary motor symptoms; nevertheless, the clinical features also include non-motor and additional motor symptoms. Krüppel-like factor 4 (KLF4), a zinc finger transcription factor, is present in several human tissues and performs a range of cell-dependent regulatory actions. Various neurological diseases, such as PD, Alzheimer's disease (AD), and Huntington's disease (HD), have been linked to KLF4, which regulates some neurophysiological and neuropathological processes in the brain. Recent data indicate that KLF4 plays a crucial regulatory role in the neurophysiological and neuropathological processes underlying PD, suggesting that it might be a viable therapeutic target for neurodegenerative diseases. This review focuses on the potential molecular mechanism underlying KLF4-mediated neuroinflammation, oxidative stress, mitochondrial dysfunction, and apoptosis. KLF4-mediated pathways are clarified by the information gathered here, and targeting them appears to be a viable therapeutic strategy for treating PD. Nevertheless, there is insufficient information on this subject, and more investigations are needed to fully understand the translational significance of the KLF4-oriented therapeutic strategy in PD.</p>","PeriodicalId":10820,"journal":{"name":"Current Medical Science","volume":" ","pages":"946-958"},"PeriodicalIF":2.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148618586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pain Medicine Specialist: Championing High-Quality Development for Neuromodulation Technology.","authors":"Ming Chen, Yang-Jia Shi, Kun Chen, Hong-Bing Xiang","doi":"10.1007/s11596-026-00209-5","DOIUrl":"10.1007/s11596-026-00209-5","url":null,"abstract":"<p><p>Neuromodulation technology, an interdisciplinary field integrating neuroscience, engineering, and clinical medicine, offers novel therapeutic paradigms for numerous intractable diseases. In pain medicine, it modulates nervous system function through electrical or chemical signals, emerging as a core approach for managing refractory pain. However, the rapid advancement of this technology has coincided with a persistent underappreciation of the core value and multidimensional roles of pain physicians. This paper systematically elucidates the essence and scope of neuromodulation technology, analyzes its unique advantages in addressing the diagnostic and therapeutic challenges of refractory pain, and reviews its rapid developmental trajectory. It critically highlights the indispensable, yet often underestimated, role of pain physicians in driving the high-quality advancement of this field. Furthermore, this paper explores safety concerns in clinical applications and highlights the need to establish robust monitoring, evaluation, and education systems. Finally, future directions for pain specialists in leading the evolution of neuromodulation are outlined.</p>","PeriodicalId":10820,"journal":{"name":"Current Medical Science","volume":" ","pages":"959-969"},"PeriodicalIF":2.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148590484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune-Mediated Inflammatory Diseases: Addressing Safety Concerns and Enhancing the Accessibility of Biosimilars.","authors":"Cláudia P Feiteira, Isabel C Tavares, Maria H L Ribeiro","doi":"10.1007/s11596-026-00212-w","DOIUrl":"10.1007/s11596-026-00212-w","url":null,"abstract":"<p><p>Immune-mediated inflammatory diseases (IMIDs), including psoriasis, lupus, multiple sclerosis, and inflammatory bowel disease, are chronic conditions characterized by immune dysregulation and excessive inflammatory cytokine expression. Biologic therapies have transformed IMID management, and the introduction of biosimilars has improved treatment accessibility by reducing costs and alleviating the burden on healthcare systems. Despite regulatory approval and demonstration of similarity to reference biologics, biosimilar adoption remains limited due to uncertainties regarding interchangeability and extrapolation, insufficient communication among stakeholders, and the nocebo effect that influences patient and physician confidence. Although regulatory agencies provide detailed guidance and European Public Assessment Reports, regulatory and perceptual barriers persist in clinical practice. This work reviews real-world and clinical trial data on switching from reference biologics to biosimilars in IMIDs and demonstrates comparable safety and efficacy outcomes. However, patient perceptions and communication strategies significantly influence treatment success. Despite the available evidence, negative perceptions and a lack of confidence persist among both patients and healthcare professionals. Promoting understanding and confidence in biosimilars can increase access and availability and, consequently, enhance the benefits associated with their wider use. Therefore, addressing educational, regulatory, and clinical practice gaps is essential for optimizing biosimilar integration in IMID management.</p>","PeriodicalId":10820,"journal":{"name":"Current Medical Science","volume":" ","pages":"881-898"},"PeriodicalIF":2.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13503507/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148204364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}